Integra LifeSciences

Q1 FY2026 EarningsQ2 FY26 revenue reached $418.8M, up 0.8% YoY and 0.7% on an organic basis. Specialty Surgery grew 1.7% YoY, while Tissue Reconstruction declined 1.9% due to prior-year backorder comparisons. Adjusted gross margin improved by 0.6pct to 61.3%, and adjusted EBITDA rose to $78.4M (18.7% margin). GAAP EPS recovered to $0.06 from a significant loss last year, while Adjusted EPS beat expectations at $0.56.